Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231919 · ClinicalTrials.gov registry record · Phase 1
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01231919: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01231919 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01231919, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER pharmacological study
- OTHER diagnostic laboratory biomarker analysis
- DRUG Akt inhibitor MK2206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01231919
The ClinicalTrials.gov registry entry for NCT01231919 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT01231919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01231919 about?
NCT01231919 is a clinical study titled "MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia". This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01231919?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-01.
What interventions are being tested in trial NCT01231919?
The interventions under investigation include: pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), Akt inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01231919?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.